DSIP and emideltide are names encountered in the same research field, but a common name is not a complete product specification. Identity matters before evidence about a preparation can be interpreted.
A label can leave important questions unanswered
The FDA's 2026 chemistry assessment evaluated emideltide free base and emideltide acetate as distinct bulk substances. It also described inconsistent naming and characterization in the submitted information.
A salt designation, a modified sequence and a finished formulation describe different properties. They should not be silently merged because their labels contain DSIP. Nor should data from a combination preparation automatically be assigned to one isolated component.
Match the study material to the claim
Interpreting a study requires identifying what the investigators administered, which route they used and what outcomes they measured. If that information is unclear, the uncertainty belongs in the interpretation.
For a commercial preparation, another question remains: does the available documentation actually establish the identity and quality of that container? A study cannot authenticate a lot, and a familiar abbreviation cannot replace appropriate characterization.
A purity percentage is also a limited statement. It must be tied to a sample, method and property measured rather than treated as a complete certificate of human suitability.
Why this is relevant to practical use questions
Dose, route and storage questions all assume that the preparation is defined. If that assumption is unresolved, copying instructions from a different material creates further uncertainty rather than resolving it.
For a legitimately prescribed medicine, the prescriber and pharmacist should reconcile product details and instructions. For research-only material, this article does not offer a workaround that makes administration appropriate.
The FDA briefing is a dated staff assessment, not itself a final regulatory determination. Its identity concerns nevertheless illustrate an enduring evidence principle: a shared name is not enough to transfer clinical findings.
Before asking whether a DSIP claim is persuasive, ask whether it is actually about the substance and finished preparation under discussion.